Emerging Therapies in the Management of HR+, HER2- Metastatic Breast Cancer - Episode 9

Exciting Ongoing Studies in the Treatment of HR+, HER2- Metastatic Breast Cancer

,

The doctors recommend using endocrine therapy-based options first-line when possible, before considering chemotherapy or antibody-drug conjugates, in order to preserve quality of life; they note exceptions could include patients with rapid progression or visceral crisis where immediate chemotherapy may be warranted, and that determining optimal sequencing requires understanding the safety profiles and efficacy data for the available regimens.